
News|Articles|May 19, 2011
Pfizer kidney cancer drug effective in phase III study
NEW YORK (Reuters) - A drug from Pfizer Inc delayed progression of advanced kidney cancer by nearly seven months, and by two months longer than a commonly used medicine, in previously treated patients, according to data from a late stage clinical trial.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
What exactly is managed care today?
3
TrumpRx launches; some experts question its long-term value
4
PBM reform. It has finally happened
5























